023sek
-1,1 %
Date:2024-04-25Time:17:29:37Latest report:Q4-2023List:First NorthTicker:ACARIX
Market Cap:213 msekEnterprise Value:178 msekNet Sales:6,24 msekEarnings:-77,8 msekEmployees:0ISIN:SE0009268717

Ratios

10-year key figure history for Acarix turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Acarix with index and moving average MA50 and MA200.

Stockprice:0,23
MA50:0,26
MA200:0,28
Price/MA200:-18,1 %
RSI (14):38,8
Price/MA50:-10,3 %

Description

Acarix AB is a Swedish medical technology company that develops innovative solutions for rapid AI-based exclusion of coronary artery disease (CAD). The CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. The CADScor System uses advanced acoustics and AI technology to non-invasively rule out CAD in less than 10 minutes, with at least 96% certainty.

Medical Equipment